Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PURPOSE: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were exclude...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Zimmer, Lisa, Vaubel, Julia, Mohr, Peter, Hauschild, Axel, Utikal, Jochen, Simon, Jan, Garbe, Claus, Herbst, Rudolf, Enk, Alexander, Kämpgen, Eckhart, Livingstone, Elisabeth, Bluhm, Leonie, Rompel, Rainer, Griewank, Klaus G., Fluck, Michael, Schilling, Bastian, Schadendorf, Dirk
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356548/
https://ncbi.nlm.nih.gov/pubmed/25761109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0118564
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados